SAMIL PHARMACEUTICAL Completes 10 Billion KRW Convertible Bond Issuance for Vietnam CMO Investment, Dilution Inevitable
SAMIL PHARMACEUTICAL has completed the issuance of 10 billion KRW in 24th unsecured private convertible bonds.
The proceeds will be used for operating funds of the Vietnam ophthalmic CMO factory and to address put options on existing exchangeable bonds.
The conversion price of 7,245 KRW is 2.8% above the current share price of 7,050 KRW, but the issuance of 1,380,262 new shares results in a 6.07% dilution, with potential total dilution including existing exchangeable bonds reaching 7.84%.
[AI Summary]This convertible bond issuance supports SAMIL PHARMACEUTICAL's growth strategy through Vietnam facility investment, but the potential dilution of up to 7.84% may undermine existing shareholder value. Short-term stock price pressure is expected, but medium to long-term business expansion effects should be balanced.
KOSPI Filing Information
Result of Issuance of Rights Offering or Equity-Related Bonds (Voluntary Disclosure)